Amgen to acquire rare diseases drugmaker Chemocentryx for $4bn
Amgen will gain access to Tavneos, Chemocentryx’s oral small molecule drug, designed to selectively inhibit the complement component…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Aug 22
Amgen will gain access to Tavneos, Chemocentryx’s oral small molecule drug, designed to selectively inhibit the complement component…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Aug 22
Through the acquisition, Gilead will obtain MiroBio’s unique I-ReSToRE drug discovery platform, along with its complete range of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Aug 22
Juvéderm Volux XC is said to be the first and only hyaluronic acid (HA) filler to receive US…
04 Aug 22
The collaboration will focus on advancing multiple existing and additional next-generation cell therapies against targets in multiple myeloma,…
03 Aug 22
Caris Life Sciences and Xencor will jointly research, develop and commercialise XmAb bispecific antibodies directed against novel targets…
03 Aug 22
Cimerli has been approved as an interchangeable product with Lucentis for all five indications, which means the drug…
02 Aug 22
The US health regulator approved Stelara as the first and only biologic targeting both cytokines interleukin (IL)-12 and…
02 Aug 22
The new strategic collaboration will leverage Sosei Heptares’ StaR technology and SBDD platform and AbbVie’s extensive neuroscience expertise,…
01 Aug 22
The EC approval is supported by data from the Phase 3 SELECT-AXIS 2 clinical trial, in which Rinvoq…
01 Aug 22
Under the new agreement with the US government, the biotechnology company will receive up to $1.74bn for 66…